The Seattle Children’s Hospital is conducting a pioneering clinical trial testing engineered immune cells as a treatment for children and young adults with a kind of brain cancer that produces the HER2 factor.
The first step in full treatment approval starts with trial testing. Those eligible for this trail are:
- Patients 26 or younger
- Those that have undergone surgery to remove a tumor
- Those that have also failed first-line therapy
Those enrolled in the trial undergo an infusion of cancer-fighting chimeric antigen receptor (CAR) T-cells directly into the region of the brain where the tumor was located compared to therapies that are injected into the blood to maximize effectiveness.
CAR T-cell therapy involves collecting a patient’s own T-cells and genetically engineering them to recognize and bind to a cancer-specific protein then destroying it.